Clinical Research Directory
Browse clinical research sites, groups, and studies.
Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19
Sponsor: South African National Blood Service
Summary
A prospective, randomized, placebo-controlled, double-blinded, phase III clinical trial of the therapeutic use of convalescent plasma in the treatment of patients with moderate to severe COVID-19
Official title: A Prospective, Randomized, Placebo-controlled, Double-blinded, Phase III Clinical Trial of the Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
102
Start Date
2020-09-21
Completion Date
2022-07-31
Last Updated
2026-05-08
Healthy Volunteers
No
Interventions
COVID-19 convalescent plasma (CCP) plus standard of care (SOC)
A single unit of approximately 200-250 mL of CCP that contains anti-SARS-CoV-2 collected by plasmapheresis from a volunteer who recovered from COVID19 with SOC as determined by local practice and guidelines.
Standard of care (SOC) plus placebo
A single unit of 200 mL normal saline with SOC as determined by local practice and guidelines
Locations (2)
Universitas Hospital
Bloemfontein, Free State, South Africa
Mitchells Plain Hospital
Cape Town, Western Cape, South Africa